Portfolio Management

3.4.2014 Portfolio Management

Pharmaceutical Leaders Seek Focused Product Portfolios

By Ryan McGuire, Research Team Leader There is a surge in portfolio management activities going on in big pharma right now. Several CEOs have announced plans to refocus their investigational pipelines and divest marketed product lines that no longer...
 

2.14.2014 Lifecycle Management

Lifecycle Management: A Love Story [Infographic]

By Nicole May, Research Analyst In this age of blockbuster drug patent cliffs, pharma has focused its attention on optimizing drug lifecycle management.  Companies are adding dedicated LCM teams and cross-functional committees to better plan and...
 

7.30.2013 Lifecycle Management

Sandoz Aims to Launch Biosimilar Version of Enbrel

By Jennifer Harrell, Research Analyst Sandoz, a generic subsidiary of Novartis and an industry leader in the development of follow-on biologics, is launching a Phase III clinical trial of a biosimilar version of Amgen’s Enbrel (etanercept).  Enbrel...
 

7.23.2013 Lifecycle Management

From Phase 3 to Post-Marketing Studies: The Journey of Aripiprazole IM (Abilify Maintena)

By Sarah Ray, Research Analyst Schizophrenia is a complex psychological disease state that distorts patients’ cognitive and emotional responses. Patients may experience positive symptoms such as delusions, hallucinations or disorganized thought...
 

7.18.2013 New Product Development

New Product Planning Teams Ramp Up Staff and Budgets for Successful Development

By Jacob Presson, Research Analyst New product planning teams are an important part of the product development cycle and portfolio management.  Assisting in the transition from an investigational product to a fully marketed one is vital for the...
 

7.16.2013 Pipeline Planning

The Debate on ‘Pay-for-Delay’ and Anti-Trust Laws

By Jennifer Harrell, Research Analyst “Pay-for-delay” deals face increasing regulatory scrutiny, although the details of their true economic implications remain murky. These deals – often the result of painstaking litigation – allow branded...
 

6.28.2013 Portfolio Management

Pfizer and Sun Settlement: Bad Omen for “At Risk” Generics Launches

By Christie Shilling, Research Analyst Once upon a time, a generics pharmaceutical company launched a generic version of another company’s branded product before patent expiration. Many years passed, with both companies in court fighting over...
 

6.12.2013 New Product Development

New Product Planning: A Tale of Three Companies

By Christie Shilling, Research Analyst It’s tempting to steer clear of considering a compound’s commercial potential early in a drug’s development.  After all, market and regulatory forces could all change drastically in the years required...
 

5.21.2013 Lifecycle Management

Less Is Definitely Not More for Counter-Generics Strategies

By Christie Shilling, Research Analyst We have a running joke among the researchers at Cutting Edge Information.  Many of the key findings from our research can be boiled down to one phrase: Start Early.  Our usual advice for pharmaceutical companies...
 

2.27.2013 New Product Development

New Product Planning Teams Take Up More Business Development Tasks

One of our recent studies showed that most pharmaceutical and biotechnology new product planning teams play at least some role in their companies’ business development activities.  While most of the companies’ new product planning units contributed to business...